September 2024
The global consumer genomics market size was estimated at US$ 1.57 billion in 2023 and is projected to grow to US$ 14.45 billion by 2033, rising at a compound annual growth rate (CAGR) of 24.85% from 2024 to 2033. The expansion of this market is being driven by an increase in the demand for direct-to-consumer genetic testing in recent times.
Unlock Infinite Advantages: Subscribe to Annual Membership
The consumer genomics market consists of two segments: consumer-driven genetic testing, which is genetic testing ordered by a health care provider in response to an informed patient request, and direct-to-consumer applications, which are genetic tests obtained directly from a commercial company without the involvement of a health care provider. Due to the possibility of consumer misinterpretation, conversations on the necessity to demonstrate clinical and analytical validity as well as clinical utility have arisen as consumer genomics has become more and more integrated with clinical applications. Practitioners have faced obstacles in terms of education and training because of clinical preparedness and interest in this information. Concurrently, the consumer genomics market has surfaced as a potentially inventive domain for contemplating health literacy and enlisting individuals in their own health and medical care.
| Company Name | Nucleus Genomics |
| Headquarters | New York, U.S., North America |
| Recent Development | In March 2024, in an effort to provide everyone with the advantages of customized treatment, Nucleus Genomics, a business that specializes in next-generation genetic testing and analysis, announced the introduction of its DNA analysis product. Consumers who have already had microarray genetic testing with other testing businesses can upload their DNA data into Nucleus' platform to learn more about their genetic susceptibility to a variety of illnesses, including breast cancer and type 2 diabetes. By using lifestyle and personal parameters like age, blood pressure, cholesterol, and BMI in its analysis, Nucleus further customizes these risk evaluations. |
| Company Name | SOFiA Genetics |
| Headquarters | Switzerland, Europe |
| Recent Development | In May 2024, a leading global provider of data-driven medicine, SOPHiA GENETICS, a cloud-native healthcare technology company, recently revealed that it is joining forces with Microsoft and NVIDIA to combine their technological and genomics expertise to provide healthcare facilities with a streamlined and scalable whole genome sequencing (WGS) analytical solution. It is expected that clients will have access to the solution by the end of 2024. SoPHiA GENETICS's new whole genome sequencing (WGS) application will enable scientists and physicians to quickly obtain fully annotated whole genome insights, enabling them to make data-driven decisions the same day. |
The most significant technical advancement in the life sciences that has made genomics possible for precision medicine, and more particularly for the life sciences, is high-throughput sequencing (NGS) and its more recent expansion to long-read sequencing. Sequencing has been more accessible due to declining costs, which has had a wider range of effects, including increased application in healthcare. All of this points to new developments in consumer genomics analytic platforms and technology. Helix, an Illumina-backed genomics business with a consumer focus, is one of the recent entries.
The use of genomic testing has moved from being uncommon to commonplace in many therapeutic settings due to outstanding advances in genomics research in recent years. While there are obvious therapeutic benefits to this kind of testing, patients should be aware that there are also new privacy hazards associated with it, including the possibility that their genetic information may be misused. There are still issues with applicants for life, long-term care, and disability insurance being discriminated against based on their genetic information. GINA is not the only law that protects patient privacy; HIPAA also limits the sharing of medical records.
Global healthcare is being revolutionized by personalized genomics, which is the combination of genetic testing and biotechnology. Genetics is a significant factor in human development since it affects a person's qualities, abilities, and general health in a variety of ways. Through genetic profiling analysis, medical interventions and medications can be customized to an individual's specific genetic traits, improving treatment outcomes and decreasing side effects. Consumer genomics acknowledges that genetics and lifestyle have complex interactions that affect health. The ability to customize one's lifestyle and health through access to one's specific genetic information results in observable and quantifiable improvements. Adopting a genome-based lifestyle can have significant effects on a person's health, enhancing their general well-being and quality of life.
The genetic relatedness segment held the largest share of the consumer genomics market in 2023. Finding missing people, paternity testing, genealogy, and family searches are just a few of the numerous applications that depend on the idea of relatedness. The application of human genetics requires the ability to draw conclusions from genetic data in an ethical manner. Ensuring accurate inference on current genetic relatedness, like family structure, and more distant genetic relatedness, like population structure, is crucial for safeguarding against false correlations in genome-wide and sequencing association studies, for instance.
The last 20 years have seen a rise in the use of genetic testing throughout the world. More than 90% of tests that are sent to GTR are not intended for research but rather for clinical use. In 2012 and 2022, respectively, there were 1081 and 6214 new genetic tests available globally. There were just 607 new genetic tests available in the U.S. in 2012, compared to 3097 in 2022.
The lifestyle, wellness & nutrition segment is estimated to grow with the fastest CAGR in the consumer genomics market during the forecast period. By analyzing your DNA, genetic testing determines your hereditary susceptibility to a range of disorders and characteristics. This can include dietary preferences like a need for antioxidants, sensitivity to gluten, and many other dietary differences linked to health aspects like metabolism, weight gain and loss. A number of these tests claim to provide insights into things like food preferences, fitness, nutrition, hazards related to health, and even genetic differences. People are able to customize anything to fit their own preferences.
North America dominated the consumer genomics market by 38% in 2023, driven by a number of variables, including a proactive approach to tailored treatment, a high frequency of illnesses connected to lifestyle, and growing consumer awareness. The area has a strong healthcare foundation, which has helped consumer genomics services become widely used. In addition, industry development has been fueled by strategic partnerships between genetic testing businesses and healthcare providers as well as by supportive regulatory environments.
In the U.S., there are key consumer genomics market players, and the country is also dominating in technological advancements. Apart from this, the government of the U.S. continuously provides resources and develops programs and schemes to conduct research and clinical development. The country also demands consumer genomics due to the growing prevalence of lifestyle-related diseases and deaths. These diseases include cardiovascular diseases, type 2 diabetes, stroke and so on.
Asia Pacific is expected to grow at the fastest rate of 23% during the forecast period. The consumer genomics market is expanding due to a number of factors, including a big and diversified population, increased disposable incomes, and growing knowledge of the advantages of genetic testing. Even though the industry is still in its infancy, rising healthcare infrastructure development and an increase in illnesses linked to a healthy lifestyle in nations like China and India present enormous opportunities for consumer genomics firms to enter this enormously large and unexplored market.
For instance,
By Application
By Region
Artificial intelligence (AI) has significantly transformed the field of genomics by merging advanced algorithms with extensive genomic data, driving major advancements in personalized medicine. In research, AI analyzes large datasets to identify patterns and relationships between genes and diseases, leading to the discovery of new biomarkers and therapeutic targets. In clinical diagnostics, AI enhances the interpretation of genomic data, improving disease diagnosis and risk assessment while enabling personalized treatment plans. This progress in AI-powered genomics also propels precision medicine, allowing healthcare providers to make more informed decisions on disease prevention, diagnosis, and treatment based on an individual's unique genetic profile, ultimately enhancing patient outcomes.
September 2024
September 2024
September 2024
September 2024
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.